Cell ther­a­py biotech Ser­no­va re­sponds to board nom­i­nees from 'con­cerned share­hold­er­s'

Cana­di­an cell ther­a­py biotech Ser­no­va is at­tempt­ing to clear the air on share­hold­er dis­sent.

Three can­di­dates are vy­ing for one board di­rec­tor seat, with two com­ing from a group of “con­cerned share­hold­ers,” as they dub them­selves, that col­lec­tive­ly own about 12% of Ser­no­va’s shares. But those two can­di­dates did not ac­cept Ser­no­va’s in­vite to its board’s for­mal re­view and eval­u­a­tion process, Ser­no­va said in a re­but­tal Thurs­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER